Peripheral zone prostate cancer localization by multiparametric magnetic resonance at 3 T: Unbiased Cancer identification by matching to histopathology

Investigative Radiology

Volumn 47, Issue 11, 2012, Pages 624-633

  Selnæs, Kirsten M ^a   Heerschap, Arend ^a,b   Jensen, Line R ^a   Tessem, May Britt ^a   Schweder, Gregor Jarosch Von ^c   Goa, Pål E ^a,c   Viset, Trond ^d   Angelsen, Anders ^e   Gribbestad, Ingrid S ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Departments of Radiology   (Norway)

^d Departments of Pathology and Medical Genetics   (Norway)

^e TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

diffusion weighted imaging; dynamic contrast enhanced MR imaging; image interpretation; magnetic resonance imaging; magnetic resonance spectroscopy; prostatic neoplasms

Indexed keywords

CHOLINE; CITRIC ACID; CREATINE; GLUCAGON;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER PATIENT; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LOGISTIC REGRESSION ANALYSIS; MALE; MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAMETRIC TEST; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTON NUCLEAR MAGNETIC RESONANCE; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; SIGNAL DETECTION; SIGNAL NOISE RATIO;

EID: 84867275004     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e318263f0fd     Document Type: Article

References (45)

1. Mazaheri Y, Shukla-Dave A, Muellner A, et al. MR imaging of the prostate in clinical practice. MAGMA. 2008;21:379-392.
2. Claus FG, Hricak H, Hattery RR. Pretreatment evaluation of prostate cancer: role of MR imaging and 1H MR spectroscopy. Radiographics. 2004; 24(suppl 1):S167-S180.
3. De Visschere PJ, De Meerleer GO, Futterer JJ, et al. Role of MRI in follow-up after focal therapy for prostate carcinoma. AJR Am J Roentgenol. 2010;194: 1427-1433.
4. Sciarra A, Barentsz J, Bjartell A, et al. Advances in magnetic resonance imaging: how they are changing the management of prostate cancer. Eur Urol. 2011;59:962-977.
5. Heidenreich A, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011;59:61-71.
6. Barentsz J, Dickinson L, Sciarra A. Re: Axel Heidenreich. Consensus criteria for the use of magnetic resonance imaging in the diagnosis and staging of prostate cancer: not ready for routine use. Eur Urol. 2011;59:495-497. Eur Urol. 2011;60(1):e5-e6.
7. Heidenreich A. Consensus criteria for the use of magnetic resonance imaging in the diagnosis and staging of prostate cancer: not ready for routine use. Eur Urol. 2011;59:495-497.
8. Ikonen S, Kivisaari L, Tervahartiala P, et al. Prostatic MR imaging. Accuracy in differentiating cancer from other prostatic disorders. Acta Radiol. 2001;42: 348-354.
9. Futterer JJ, Heijmink SW, Scheenen TW, et al. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology. 2006;241:449-458.
10. Haider MA, van der Kwast TH, Tanguay J, et al. Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. AJR Am J Roentgenol. 2007;189:323-328.
11. Turkbey B, Pinto PA, Mani H, et al. Prostate cancer: value of multiparametric MR imaging at 3 T for detection-histopathologic correlation. Radiology. 2010; 255:89-99.
12. Langer DL, van der Kwast TH, Evans AJ, et al. Prostate cancer detection with multi-parametric MRI: logistic regression anal-Sis of quantitative T2, diffusionweighted imaging, and dynamic contrast-enhanced MRI. J Magn Reson Imaging. 2009;30:327-334.
13. Mazaheri Y, Shukla-Dave A, Hricak H, et al. Prostate cancer: identification with combined diffusion-weighted MR imaging and 3D 1H MR spectroscopic imagingVcorrelation with pathologic findings. Radiology. 2008;246:480-488.
14. Dickinson L, Ahmed HU, Allen C, et al. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol. 2011;59:477-494.
15. Kurhanewicz J, Swanson MG, Nelson SJ, et al. Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer. J Magn Reson Imaging. 2002;16:451-463.
16. Kurhanewicz J, Vigneron DB, Nelson SJ, et al. Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: detection via localized proton spectroscopy. Urology. 1995;45:459-466.
17. Issa B. In vivo measurement of the apparent diffusion coefficient in normal and malignant prostatic tissues using echo-planar imaging. J Magn Reson Imaging. 2002;16:196-200.
18. Somford DM, Hambrock T, Hulsbergen-van de Kaa CA, et al. Initial experience with identifying high-grade prostate cancer using diffusion-weighted MR imaging (DWI) in patients with a Gleason score G/= 3 + 3 = 6 upon schematic TRUS-guided biopsy: a radical prostatectomy correlated series. Invest Radiol. 2012;47:153-158.
19. Fuchsjager M, Shukla-Dave A, Akin O, et al. Prostate cancer imaging. Acta Radiol. 2008;49:107-120.
20. Afaq A, Koh DM, Padhani A, et al. Clinical utility of diffusion-weighted magnetic resonance imaging in prostate cancer. BJU Int. 2011;108:1716-1722.
21. Padhani AR, Gapinski CJ, Macvicar DA, et al. Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA. Clin Radiol. 2000;55:99-109.
22. Hoeks CM, Barentsz JO, Hambrock T, et al. Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology. 2011;261: 46-66.
23. Kitajima K, Kaji Y, Fukabori Y, et al. Prostate cancer detection with 3 T MRI: comparison of diffusion-weighted imaging and dynamic contrast-enhanced MRI in combination with T2-weighted imaging. J Magn Reson Imaging. 2010; 31:625-631.
24. Yakar D, Heijmink SW, Hulsbergen-van de Kaa CA, et al. Initial results of 3-dimensional 1H-magnetic resonance spectroscopic imaging in the localization of prostate cancer at 3 Tesla: should we use an endorectal coil? Invest Radiol. 2011;46:301-306.
25. Scheenen TW, Heijmink SW, Roell SA, et al. Three-dimensional proton MR spectroscopy of human prostate at 3 T without endorectal coil: feasibility. Radiology. 2007;245:507-516.
26. Langer DL, van der Kwast TH, Evans AJ, et al. Intermixed normal tissue within prostate cancer: effect on MR imaging measurements of apparent diffusion coefficient and T2-sparse versus dense cancers. Radiology. 2008;249:900-908.
27. Giusti S, Caramella D, Fruzzetti E, et al. Peripheral zone prostate cancer. Pretreatment evaluation with MR and 3D (1)H MR spectroscopic imaging: correlation with pathologic findings. Abdom Imaging. 2010;35:757-763.
28. Scheenen TW, Gambarota G, Weiland E, et al. Optimal timing for in vivo 1HMR spectroscopic imaging of the human prostate at 3T. Magn Reson Med. 2005;53:1268-1274.
29. Scheenen TW, Klomp DW, Roll SA, et al. Fast acquisition-weighted threedimensional proton MR spectroscopic imaging of the human prostate. Magn Reson Med. 2004;52:80-88.
30. Sobin LH, Wittekind C. TNM Classification of Malignant Tumours. 6th ed. New York, NY: John Wiley & Sons, Inc; 2002.
31. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974;111: 58-64.
32. Alonzi R, Taylor NJ, Stirling JJ, et al. Reproducibility and correlation between quantitative and semiquantitative dynamic and intrinsic susceptibility-weighted MRI parameters in the benign and malignant human prostate. J Magn Reson Imaging. 2010;32:155-164.
33. Scheenen TW, Futterer J, Weiland E, et al. Discriminating cancer from noncancer tissue in the prostate by 3-dimensional proton magnetic resonance spectroscopic imaging: a prospective multicenter validation study. Invest Radiol. 2011;46:25-33.
34. Sato C, Naganawa S, Nakamura T, et al. Differentiation of noncancerous tissue and cancer lesions by apparent diffusion coefficient values in transition and peripheral zones of the prostate. J Magn Reson Imaging. 2005;21:258-262.
35. Reinsberg SA, Payne GS, Riches SF, et al. Combined use of diffusion-weighted MRI and 1HMR spectroscopy to increase accuracy in prostate cancer detection. AJR Am J Roentgenol. 2007;188:91-98.
36. Desouza NM, Reinsberg SA, Scurr ED, et al. Magnetic resonance imaging in prostate cancer: the value of apparent diffusion coefficients for identifying malignant nodules. Br J Radiol. 2007;80:90-95.
37. Pickles MD, Gibbs P, Sreenivas M, et al. Diffusion-weighted imaging of normal and malignant prostate tissue at 3.0 T. J Magn Reson Imaging. 2006;23:130-134.
38. Delongchamps NB, Rouanne M, Flam T, et al. Multiparametric magnetic resonance imaging for the detection and localization of prostate cancer: combination of T2-weighted, dynamic contrast-enhanced and diffusion-weighted imaging. BJU Int. 2011;107:1411-1418.
39. Gibbs P, Liney GP, Pickles MD, et al. Correlation of ADC and T2 measurements with cell density in prostate cancer at 3.0 Tesla. Invest Radiol. 2009;44:572-576.
40. Langer DL, van der Kwast TH, Evans AJ, et al. Prostate tissue composition and MR measurements: investigating the relationships between ADC, T2, Ktrans, Ve, and corresponding histologic features. Radiology. 2010;255: 485-494.
41. Mueller-Lisse UG, Scherr MK. Proton MR spectroscopy of the prostate. Eur J Radiol. 2007;63:351-360.
42. van Dorsten FA, van der Graaf M, Engelbrecht MR, et al. Combined quantitative dynamic contrast-enhanced MR imaging and (1)H MR spectroscopic imaging of human prostate cancer. J Magn Reson Imaging. 2004;20:279-287.
43. Galbraith SM, Lodge MA, Taylor NJ, et al. Reproducibility of dynamic contrastenhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative anal-Sis. NMR Biomed. 2002;15:132-142.
44. Xu J, Humphrey PA, Kibel AS, et al. Magnetic resonance diffusion characteristics of histologically defined prostate cancer in humans. Magn Reson Med. 2009;61:842-850.
45. Peduzzi P, Concato J, Kemper E, et al. A simulation study of the number of events per variable in logistic regression anal-Sis. J Clin Epidemiol. 1996;49: 1373-1379.